Early Triple Negative Breast Cancer: Clinical Trials

1 completed, 1 withdrawn. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Completed 1, Withdrawn 1

Follow Early Triple Negative Breast Cancer: new trials by email Literature Review of Early Triple Negative Breast Cancer trials Research Report on Early Triple Negative Breast Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) Pembrolizumab, Paclitaxel, Carboplatin - Early Triple Negative Breast Cancer	Phase 2	Withdrawn	Merck Sharp & Dohme LLC		2025-03-26	2026-02-19
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy Doxorubicin, Paclitaxel, Cisplatin - Early Triple Negative Breast Cancer	Phase 2	Completed	Russian Academy of Medical Sciences	41	2011-08-01	2015-11-03

Narrower conditions

Triple Negative Breast Neoplasms (2)  ·  Breast Neoplasms (1)

Broader conditions

Breast Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Breast Neoplasms (1)

Interventions

Doxorubicin (2)  ·  Paclitaxel (2)  ·  Capecitabine (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Epirubicin (1)  ·  olaparib (1)  ·  pembrolizumab (1)

Sponsors

Merck Sharp & Dohme LLC (1)  ·  Russian Academy of Medical Sciences (1)

Countries

Russia (1)  ·  Taiwan (1)  ·  United States (1)